Minimally invasive surgery (MIS) may preserve daily activities in patients over 80 with gastrointestinal and hepatobiliary cancers. Severe postoperative decline in daily living activities was 5.7% for MIS vs. 9.5% for open surgery, suggesting MIS is safer. 90-day readmission rates were lower for MIS at 16.6% compared to 22.3% for open surgery. This approach is […]

Laparoscopic right hemihepatectomy offers benefits that may improve patient recovery despite its complexity. Laparoscopic patients had a shorter time to functional recovery (5 vs. 6 days) and shorter hospital stays (5 vs. 6 days). Operating times were longer for laparoscopic procedures (332 vs. 263 min), but other outcomes showed no significant differences. Surgeons should consider […]

Minimally invasive approaches in liver and pancreatic surgery show significant cost advantages. Laparoscopic ($77,657) and robotic ($89,713) surgeries have lower median hospital charges compared to open surgery ($111,051) (p < .001). In liver resections, laparoscopic surgery results in adjusted charge reductions of $23,564 overall, and $14,140 for early discharges. Surgeons should consider minimally invasive techniques […]

Neoadjuvant GOLP therapy significantly enhances event-free survival in patients with resectable high-risk intrahepatic cholangiocarcinoma. Median event-free survival was 18.0 months with GOLP, compared to 8.7 months in the control group (p<0.001). Overall survival at 24 months was 79% for the neoadjuvant group vs. 61% for controls (hazard ratio 0.43). Expect lower-grade adverse events overall, with […]

Medicaid expansion improves survival and surgical access for pancreatic cancer patients. Residents in states with early, on-time, and late Medicaid expansion had 2-year mortality reductions (hazard ratios ranging from 0.91 to 0.94). There was a 19% increase in the odds of surgical resection with Medicaid expansion (odds ratio 1.19). Outcomes improved primarily after three years […]

Transplanting liver patients who respond to atezolizumab-bevacizumab is promising for those with intermediate and advanced hepatocellular carcinoma. Recurrence-free survival is 90% and overall survival is 94% at two years post-transplant. Acute rejection rates are 25%, but remain manageable; 62.5% had complications within 90 days of transplant. Surgical teams should consider immunotherapy response when selecting candidates […]

Dynamic radiomic features from MRI can predict complete response in hepatocellular carcinoma (HCC) post-immune therapy, critical for surgical planning. A delta radiomic model achieved an AUC of 0.835 in predicting lesion-level complete response compared to 0.483 for baseline models. Combining radiomics with serum AFP response boosted predictive accuracy, yielding AUCs of 0.920 in the test […]

Atezolizumab-bevacizumab shows promising long-term survival for patients with unresectable hepatocellular carcinoma. Median overall survival is 19.7 months with a 36-month survival rate of 30%. 36.8% experienced grade ≥3 adverse events; 14.1% had liver decompensation not related to tumor progression. Surgeons should consider multidisciplinary approaches, as 14.9% of patients underwent additional surgical or locoregional procedures post-treatment. […]